BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 16431016)

  • 1. Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons.
    Hult M; Shafqat N; Elleby B; Mitschke D; Svensson S; Forsgren M; Barf T; Vallgårda J; Abrahmsen L; Oppermann U
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):26-33. PubMed ID: 16431016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species.
    Arampatzis S; Kadereit B; Schuster D; Balazs Z; Schweizer RA; Frey FJ; Langer T; Odermatt A
    J Mol Endocrinol; 2005 Aug; 35(1):89-101. PubMed ID: 16087724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinctive molecular inhibition mechanisms for selective inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
    Tu H; Powers JP; Liu J; Ursu S; Sudom A; Yan X; Xu H; Meininger D; Degraffenreid M; He X; Jaen JC; Sun D; Labelle M; Yamamoto H; Shan B; Walker NP; Wang Z
    Bioorg Med Chem; 2008 Oct; 16(19):8922-31. PubMed ID: 18789704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
    Schuster D; Maurer EM; Laggner C; Nashev LG; Wilckens T; Langer T; Odermatt A
    J Med Chem; 2006 Jun; 49(12):3454-66. PubMed ID: 16759088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice.
    Johansson L; Fotsch C; Bartberger MD; Castro VM; Chen M; Emery M; Gustafsson S; Hale C; Hickman D; Homan E; Jordan SR; Komorowski R; Li A; McRae K; Moniz G; Matsumoto G; Orihuela C; Palm G; Veniant M; Wang M; Williams M; Zhang J
    J Med Chem; 2008 May; 51(10):2933-43. PubMed ID: 18419108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The discovery of 2-anilinothiazolones as 11beta-HSD1 inhibitors.
    Yuan C; St Jean DJ; Liu Q; Cai L; Li A; Han N; Moniz G; Askew B; Hungate RW; Johansson L; Tedenborg L; Pyring D; Williams M; Hale C; Chen M; Cupples R; Zhang J; Jordan S; Bartberger MD; Sun Y; Emery M; Wang M; Fotsch C
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6056-61. PubMed ID: 17919905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benzothiazole derivatives as novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
    Su X; Vicker N; Ganeshapillai D; Smith A; Purohit A; Reed MJ; Potter BV
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):214-7. PubMed ID: 16325333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice.
    Alberts P; Engblom L; Edling N; Forsgren M; Klingström G; Larsson C; Rönquist-Nii Y; Ohman B; Abrahmsén L
    Diabetologia; 2002 Nov; 45(11):1528-32. PubMed ID: 12436336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors with oleanan and ursan scaffolds.
    Blum A; Favia AD; Maser E
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):132-6. PubMed ID: 18822345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of murine 11 beta-hydroxysteroid dehydrogenase 1: an important therapeutic target for diabetes.
    Zhang J; Osslund TD; Plant MH; Clogston CL; Nybo RE; Xiong F; Delaney JM; Jordan SR
    Biochemistry; 2005 May; 44(18):6948-57. PubMed ID: 15865440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
    Su X; Vicker N; Trusselle M; Halem H; Culler MD; Potter BV
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):169-73. PubMed ID: 18775471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 17Beta-estradiol inhibits 11beta-hydroxysteroid dehydrogenase type 1 activity in rodent adipocytes.
    Tagawa N; Yuda R; Kubota S; Wakabayashi M; Yamaguchi Y; Kiyonaga D; Mori N; Minamitani E; Masuzaki H; Kobayashi Y
    J Endocrinol; 2009 Jul; 202(1):131-9. PubMed ID: 19380458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Piperazine sulfonamides as potent, selective, and orally available 11beta-hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyperinsulinemia model.
    Xiang J; Wan ZK; Li HQ; Ipek M; Binnun E; Nunez J; Chen L; McKew JC; Mansour TS; Xu X; Suri V; Tam M; Xing Y; Li X; Hahm S; Tobin J; Saiah E
    J Med Chem; 2008 Jul; 51(14):4068-71. PubMed ID: 18578516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural characterization and pharmacodynamic effects of an orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor.
    Hale C; Véniant M; Wang Z; Chen M; McCormick J; Cupples R; Hickman D; Min X; Sudom A; Xu H; Matsumoto G; Fotsch C; St Jean DJ; Wang M
    Chem Biol Drug Des; 2008 Jan; 71(1):36-44. PubMed ID: 18069989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of adamantyl ethanone derivatives as potent 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors.
    Su X; Pradaux-Caggiano F; Thomas MP; Szeto MW; Halem HA; Culler MD; Vicker N; Potter BV
    ChemMedChem; 2010 Jul; 5(7):1026-44. PubMed ID: 20486152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-(S)-phenethylaminothiazolones as potent, orally efficacious inhibitors of 11beta-hydroxysteriod dehydrogenase type 1.
    Jean DJ; Yuan C; Bercot EA; Cupples R; Chen M; Fretland J; Hale C; Hungate RW; Komorowski R; Veniant M; Wang M; Zhang X; Fotsch C
    J Med Chem; 2007 Feb; 50(3):429-32. PubMed ID: 17266194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docking-based 3D-QSAR study for 11beta-HSD1 inhibitors.
    Lee JH; Kang NS; Yoo SE
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2479-90. PubMed ID: 18314331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
    Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
    Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice.
    Véniant MM; Hale C; Komorowski R; Chen MM; St Jean DJ; Fotsch C; Wang M
    Diabetes Obes Metab; 2009 Feb; 11(2):109-17. PubMed ID: 18479468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel sulfonamides as potent and selective inhibitors against human and mouse 11β-hydroxysteroid dehydrogenase type 1.
    Xia G; Liu L; Xue M; Liu H; Yu J; Li P; Chen Q; Xiong B; Liu X; Shen J
    Mol Cell Endocrinol; 2012 Jul; 358(1):46-52. PubMed ID: 22410288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.